| Literature DB >> 29216234 |
Bertrand Olliac1,2,3, Graciela Crespin4, Marie-Christine Laznik5, Oussama Cherif Idrissi El Ganouni6, Jean-Louis Sarradet4, Colette Bauby4,7, Anne-Marie Dandres4,7, Emeline Ruiz4, Claude Bursztejn8, Jean Xavier1,9, Bruno Falissard10, Nicolas Bodeau1, David Cohen1,9, Catherine Saint-Georges1,9,11.
Abstract
BACKGROUND: The need for early treatment of autism spectrum disorders (ASD) necessitates early screening. Very few tools have been prospectively tested with infants of less than 12 months of age. The PREAUT grid is based on dyadic assessment through interaction and shared emotion and showed good metrics for predicting ASD in very-high-risk infants with West syndrome.Entities:
Mesh:
Year: 2017 PMID: 29216234 PMCID: PMC5720624 DOI: 10.1371/journal.pone.0188831
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart.
Significant associations between a positive PREAUT at 4 and 9 months and CHAT items.
| CHAT Key item | |||||
| odds [95%CI] | Adjusted | odds [95%CI] | Adjusted | ||
| A1: Rough and tumble play | 1.65 [0.04–10.39] | 1.00 | 2.73 [0.53–8.79] | 0.46 | |
| A2: Social interest | 6.38 [0.71–27.07] | 0.46 | 5.13 [0.99–16.79] | 0.36 | |
| A3: Motor development | 17.17 [3.14–61.54] | 0.03* | 8.99 [1.71–30.3] | 0.14 | |
| A4: Social play | 3.88 [0.43–16.25] | 0.64 | 4.26 [1.08–12.16] | 0.31 | |
| A5: Pretend play | X | 11.44 [3.61–31.32] | 0.00* | 3.33 [0.85–9.46] | 0.46 |
| A6: Protoimperative pointing | 5.4 [0.6–22.8] | 0.49 | 6.03 [1.52–17.38] | 0.14 | |
| A7: Protodeclarative pointing | X | 8.83 [1.64–30.87] | 0.11 | 8.28 [2.47–22] | 0.02* |
| A8: Functional play | 7.02 [1.31–24.4] | 0.15 | 5.05 [1.28–14.48] | 0.20 | |
| A9: Showing | 7.5 [1.82–23.21] | 0.06 | 5.14 [1.55–13.47] | 0.11 | |
| B1: Eye contact | 0 [0–26.5] | 1.00 | 3.37 [0.08–21.24] | 0.53 | |
| B2: Following a point | X | 7.46 [1.39–25.96] | 0.15 | 6.78 [2.03–17.9] | 0.05* |
| B3: Pretend play | X | 7.38 [2.66–18.99] | 0.00* | 3.71 [1.54–8.05] | 0.06* |
| B4: Protodeclarative pointing | X | 6.03 [2.26–15.34] | 0.01* | 2.18 [0.86–4.85] | 0.46 |
| B5: Tower of blocks | 5.19 [1.65–14.07] | 0.06 | 2.35 [0.8–5.71] | 0.46 | |
| odds [95% CI] | p value | odds [95%CI] | p value | ||
| CHAT medium risk (A7, B4) | 18.01 [3.29–64.79] | 0.00 | 12.31 [3.04–36.76] | 0.00 | |
| CHAT high risk (A5, A7, B2, B3, B4) | 78.02 [7.27–469.79] | 0.00 | 38.09 [3.65–220.33] | 0.00 | |
Estimations of PPV, NPV, specificity, and sensitivity for ASD (top) and neurodevelopmental disorders with each screening tool.
| Screened individuals | True positives | False positives | False negatives | True negatives | PPV (%) | NPV (%) | Specificity (%) | Sensitivity (%) | |
| P4 | 4,755 | 5.60–5.79 | 16.21–16.40 | 21.58–30.39 | 4,702.61–4,711.42 | 25.4–26.3 | 99.3–- 99.5 | 99.6–99.6 | 16.0–20.6 |
| P9 | 4,530 | 8.29–14.92 | 26.08–32.71 | 18.89–21.26 | 4,467.74–4,470.11 | 20.2–36.4 | 99.5–99.6 | 99.3–99.4 | 30.5–41.2 |
| C24 | 4,835 | 9.84–12.28 | 32.72–35.16 | 17.34–23.90 | 4,766.1–4,772.66 | 25.9–27.3 | 99.5–99.6 | 99.3–99.3 | 33.9–41.5 |
| All together P4 or P9 or C24 | 4,835 | 19–28 | 72–81 | 8–9 | 4,726–4,727 | 19.0–28.0 | 99.8–99.8 | 98.3–98.5 | 67.9–77.7 |
| P4 | 4,755 | 11.40–11.58 | 10.42–10.60 | 28.78–37.60 | 4,695.40–4,704.22 | 51.8–52.6 | 99.2–99.4 | 99.8–99.8 | 23.5–28.4 |
| P9 | 4,530 | 13.58–18.62 | 22.38–27.42 | 26.60–30.56 | 4,458.44–4,462.40 | 33.12–45.4 | 99.3–99.4 | 99.4–99.5 | 33.8–37.9 |
| C24 | 4,835 | 13.10–16.37 | 28.63–31.89 | 27.07–32.81 | 4,757.19–4,762.93 | 29.12–36.4 | 99.3–99.4 | 99.3–99.4 | 33.3–33.6 |
| All together P4 or P9 or C24 | 4,835 | 32–41 | 59–68 | 8–9 | 4,726–4,727 | 32–41 | 99.8–99.8 | 98.6–98.8 | 79.6–83.4 |
* Some individuals were positive by several tools. The number of Individuals was rounded to the nearest integer. P4: PREAUT at 4 months, P9: PREAUT at 9 months, C24: CHAT at 24 months
Screenings in the first 2 years of life in community-based samples: Prospective studies with available psychometric data.
| Age of screening in months (mean) | Sample size (N) | PPV for ASD (%) (bc = best cutoff) | Estimated Se (%) | Estimated Sp (%) | |||
|---|---|---|---|---|---|---|---|
| Current study | 4 | 4,755 | 25.4–26.3 | 16.0–20.6 | 99.6–99.6 | ||
| 9 | 4,530 | 20.2–36.4 | 30.5–41.2 | 99.3–99.4 | |||
| CHAT | 24 | 4,835 | 25.9–27.3 | 33.9–41.5 | 99.3–99.3 | ||
| PREAUT and CHAT | 4/9/24 | 4,835 | 19.0–28.0 | 67.9–77.7 | 98.3–98.5 | ||
| (Pierce, et al., 2011) | [ | 12 | 10,479 | 17 | - | - | |
| (Wetherby, et al., 2008) | [ | 6-8/9-11/12-14 | 100/259/330 | 7/13/7 | 20/77/91 | - | |
| (Turner-Brown, et al., 2013) | [ | 12 | 699 | 31 (bc) | <44 (bc) | ||
| (Lung, et al., 2011) | [ | 6 | 1,783 | 19 (bc) | - | - | |
| " | " | 18 | 1,618 | 21 (bc) | - | - | |
| (Barbaro & Dissanayake, 2010) | [ | 12/18/24 | 20,770 | 90/82/80 | Total Se = 83.8 | 99.8 | |
| (Dietz, et al., 2006) | [ | 14–30 (m = 16) | 31,724 | 24 | - | - | |
| (Mieke Dereu, et al., 2010) | [ | 3–39 (m = 16) | 6808 | 7 | 80 | 94 | |
| (Gillian Baird, et al., 2000) | [ | 18 | 16.235 | 59 | 21 | 99. | |
| 1-stage | " | " | 18 | " | 8 | 35 | 97.7 |
| 1-stage | (VanDenHeuvel, Fitzgerald, Greiner, & Perry, 2007) | [ | 18 | 2,117 | 58 | - | |
| (Kleinman, et al., 2008) | [ | 16–30 (m = 20) | 3,309 | 65 | - | - | |
| /F | (Robins, 2008) | [ | 16–27 (m = 21) | 4,799 | 57 (outcome 24 mo) | - | - |
| /F | (Pandey, et al., 2008) | [ | 16–23 (m = 18) | 4,265 | 28 | - | - |
| /F | (Chlebowski, Robins, Barton, & Fein, 2013) | [ | 16–30 (m = 20) | 18,989 | 54 | - | - |
| /F | (Windham, et al., 2014) | [ | 16–30 | 1,760 | 26 | - | - |
| /F | (Robins, et al., 2014) | [ | 16–31 (m = 21) | 16,071 | 47.5 (bc) | 85 | 99 |
| modified | (Kamio, et al., 2014) | [ | 18 | 1,851 | 45.5 | 47.6 | 98.6 |
| (Stenberg, et al., 2014) | [ | 18 | 52,026 | 1.5 | 34 | 93% |